Skip to main content
Top
Published in: Tumor Biology 11/2014

01-11-2014 | Research Article

Depression of testes-specific protease 50 (TSP50) inhibits cell proliferation and induces apoptosis in laryngocarcinoma

Author: Xiaopeng Zhang

Published in: Tumor Biology | Issue 11/2014

Login to get access

Abstract

Testes-specific protease 50 (TSP50) is a potential cancer-associated gene that may be involved in human laryngocarcinoma. The present study aimed to investigate suppressive effects on the HEp2 human laryngocarcinoma cell line by transfection with TSP50-specific short hairpin RNA (shRNA). Western blot analysis was used to detect the expression levels of TSP50. MTT assay was used to evaluate cell proliferation. Wound healing was used in cell migration and invasion assays to evaluate the cell exercise capacity. Nuclear staining assay was used to evaluate cell apoptosis after knockdown of TSP50. Expression levels of TSP50 protein in the shRNA group were downregulated successfully by transfection, and the knockdown of endogenous TSP50 in HEp2 cells greatly inhibited nuclear factor κB (NF-κB) activity. MTT results showed that the cell proliferation in the shRNA group was significantly more depressed than that in the blank (P < 0.05) and negative control groups (P < 0.05). Additionally, a decreased number of migrated cells in the shRNA group was observed (P < 0.05) using a cell migration and invasion assay. Moreover, knockdown of endogenous TSP50 expression can induce apoptosis in HEp2 Cells. These data indicated that knockdown of TSP50 may cause inhibition of proliferation, migration, and invasion of HEp2 cells. This study provides a new perspective in understanding the molecular mechanisms underlying the progression of laryngocarcinoma and offers a potential therapeutic target for laryngocarcinoma.
Literature
1.
3.
go back to reference Yuan L, Shan J, De Risi D, Broome J, Lovecchio J, Gal D, et al. Isolation of a novel gene, TSP50, by a hypomethylated DNA fragment in human breast cancer. Cancer Res. 1999;59:3215–21.PubMed Yuan L, Shan J, De Risi D, Broome J, Lovecchio J, Gal D, et al. Isolation of a novel gene, TSP50, by a hypomethylated DNA fragment in human breast cancer. Cancer Res. 1999;59:3215–21.PubMed
4.
go back to reference Shan J, Yuan L, Xiao Q, Chiorazzi N, Budman D, Teichberg S, et al. TSP50, a possible protease in human testes, is activated in breast cancer epithelial cells. Cancer Res. 2002;62:290–4.PubMed Shan J, Yuan L, Xiao Q, Chiorazzi N, Budman D, Teichberg S, et al. TSP50, a possible protease in human testes, is activated in breast cancer epithelial cells. Cancer Res. 2002;62:290–4.PubMed
5.
go back to reference Song ZB, Bao YL, Zhang Y, Mi XG, Wu P, Wu Y, et al. Testes-specific protease 50 (TSP50) promotes cell proliferation through the activation of the NF-kappa beta (NF-kappaB) signaling pathway. Biochem J. 2011;436:457–67.PubMedCrossRef Song ZB, Bao YL, Zhang Y, Mi XG, Wu P, Wu Y, et al. Testes-specific protease 50 (TSP50) promotes cell proliferation through the activation of the NF-kappa beta (NF-kappaB) signaling pathway. Biochem J. 2011;436:457–67.PubMedCrossRef
6.
go back to reference Li YY, Bao YL, Song ZB, Sun LG, Wu P, Zhang Y, et al. The threonine protease activity of testes-specific protease 50 (TSP50) is essential for its function in cell proliferation. PLoS One. 2012;7:e35030.PubMedCentralPubMedCrossRef Li YY, Bao YL, Song ZB, Sun LG, Wu P, Zhang Y, et al. The threonine protease activity of testes-specific protease 50 (TSP50) is essential for its function in cell proliferation. PLoS One. 2012;7:e35030.PubMedCentralPubMedCrossRef
7.
go back to reference Xu H, Shan J, Jurukovski V, Yuan L, Li J, Tian K. TSP50 encodes a testis specific protease and is negatively regulated by p53. Cancer Res. 2007;67:1239–45.PubMedCrossRef Xu H, Shan J, Jurukovski V, Yuan L, Li J, Tian K. TSP50 encodes a testis specific protease and is negatively regulated by p53. Cancer Res. 2007;67:1239–45.PubMedCrossRef
8.
go back to reference Zhou L, Bao YL, Zhang Y, Wu Y, Yu CL, Huang YX, et al. Knockdown of TSP50 inhibits cell proliferation and induces apoptosis in P19 cells. IUBMB Life. 2010;62:825–32.PubMedCrossRef Zhou L, Bao YL, Zhang Y, Wu Y, Yu CL, Huang YX, et al. Knockdown of TSP50 inhibits cell proliferation and induces apoptosis in P19 cells. IUBMB Life. 2010;62:825–32.PubMedCrossRef
9.
go back to reference Zheng L, Xie G, Duan G, Yan X, Li Q. High expression of testes-specific protease 50 is associated with poor prognosis in colorectal carcinoma. PLoS One. 2011;6:e22203.PubMedCentralPubMedCrossRef Zheng L, Xie G, Duan G, Yan X, Li Q. High expression of testes-specific protease 50 is associated with poor prognosis in colorectal carcinoma. PLoS One. 2011;6:e22203.PubMedCentralPubMedCrossRef
10.
go back to reference Zhang Y, Zhou L, Bao YL, Wu Y, Yu CL, Huang YX, et al. Butyrate induces cell apoptosis through activation of JNK MAP kinase pathway in human colon cancer RKO cells. Chem Biol Interact. 2010;185:174–81.PubMedCrossRef Zhang Y, Zhou L, Bao YL, Wu Y, Yu CL, Huang YX, et al. Butyrate induces cell apoptosis through activation of JNK MAP kinase pathway in human colon cancer RKO cells. Chem Biol Interact. 2010;185:174–81.PubMedCrossRef
11.
go back to reference Zhang Y, Bao YL, Yang MT, Wu Y, Yu CL, Huang YX, et al. Activin A induces SLC5A8 expression through the Smad3 signaling pathway in human colon cancer RKO cells. Int J Biochem Cell Biol. 2010;42:1964–72.PubMedCrossRef Zhang Y, Bao YL, Yang MT, Wu Y, Yu CL, Huang YX, et al. Activin A induces SLC5A8 expression through the Smad3 signaling pathway in human colon cancer RKO cells. Int J Biochem Cell Biol. 2010;42:1964–72.PubMedCrossRef
12.
go back to reference Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, Calin GA, et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet. 2009;41:365–70.PubMedCrossRef Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, Calin GA, et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet. 2009;41:365–70.PubMedCrossRef
13.
go back to reference Doerfler W, Hohlweg U, Müller K, Remus R, Heller H, Hertz J. Foreign DNA integration—perturbations of the genome—oncogenesis. Ann N Y Acad Sci. 2001;945:276–88.PubMedCrossRef Doerfler W, Hohlweg U, Müller K, Remus R, Heller H, Hertz J. Foreign DNA integration—perturbations of the genome—oncogenesis. Ann N Y Acad Sci. 2001;945:276–88.PubMedCrossRef
14.
go back to reference Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550–3.PubMedCrossRef Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550–3.PubMedCrossRef
15.
go back to reference DiDonato J, Mercurio F, Rosette C, Wu-Li J, Suyang H, Ghosh S, et al. Mapping of the inducible IκB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol. 1996;16:1295–304.PubMedCentralPubMed DiDonato J, Mercurio F, Rosette C, Wu-Li J, Suyang H, Ghosh S, et al. Mapping of the inducible IκB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol. 1996;16:1295–304.PubMedCentralPubMed
16.
go back to reference Lallena MJ, Diaz-Meco MT, Bren G, Payá CV, Moscat J. Activation of IκB kinase β by protein kinase C isoforms. Mol Cell Biol. 1999;19:2180–8.PubMedCentralPubMed Lallena MJ, Diaz-Meco MT, Bren G, Payá CV, Moscat J. Activation of IκB kinase β by protein kinase C isoforms. Mol Cell Biol. 1999;19:2180–8.PubMedCentralPubMed
17.
go back to reference Sgambato A, Cittadini A, Faraglia B, Weinstein IB. Multiple functions of p27 (Kip1) and its alterations in tumor cells: a review. J Cell Physiol. 2000;183:18–27.PubMedCrossRef Sgambato A, Cittadini A, Faraglia B, Weinstein IB. Multiple functions of p27 (Kip1) and its alterations in tumor cells: a review. J Cell Physiol. 2000;183:18–27.PubMedCrossRef
18.
go back to reference Kothapalli D, Zhao L, Hawthorne EA, Cheng Y, Lee E, Puré E, et al. Hyaluronan and CD44 antagonize mitogen-dependent cyclin D1 expression in mesenchymal cells. J Cell Biol. 2007;176:535–44.PubMedCentralPubMedCrossRef Kothapalli D, Zhao L, Hawthorne EA, Cheng Y, Lee E, Puré E, et al. Hyaluronan and CD44 antagonize mitogen-dependent cyclin D1 expression in mesenchymal cells. J Cell Biol. 2007;176:535–44.PubMedCentralPubMedCrossRef
20.
go back to reference Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ, Sledge Jr GW. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol. 1997;17:3629–39.PubMedCentralPubMed Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ, Sledge Jr GW. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol. 1997;17:3629–39.PubMedCentralPubMed
21.
go back to reference Rayet B, Gélinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999;18:6938–47.PubMedCrossRef Rayet B, Gélinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999;18:6938–47.PubMedCrossRef
22.
go back to reference Lee RJ, Albanese C, Fu M, D’Amico M, Lin B, Watanabe G, et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol. 2000;20:672–83.PubMedCentralPubMedCrossRef Lee RJ, Albanese C, Fu M, D’Amico M, Lin B, Watanabe G, et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol. 2000;20:672–83.PubMedCentralPubMedCrossRef
Metadata
Title
Depression of testes-specific protease 50 (TSP50) inhibits cell proliferation and induces apoptosis in laryngocarcinoma
Author
Xiaopeng Zhang
Publication date
01-11-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2090-y

Other articles of this Issue 11/2014

Tumor Biology 11/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine